eligibility_summary
Eligibility: Include patients enrolled in the Kesimpta Go Program who provided informed consent and started ofatumumab. Exclude patients with no demographic data, those not linkable across required data sources (enrollment form, pharmacy claims, program database), or those with three or more treatment interruptions (“on hold”).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06854341 is a completed, non-interventional Canadian real-world cohort study assessing persistence on ofatumumab (Kesimpta) in adults with relapsing-remitting multiple sclerosis enrolled in the Kesimpta Go Program. Drug: Ofatumumab, a fully human anti-CD20 monoclonal antibody (subcutaneous biologic). Mechanism: binds a specific CD20 epitope on B lymphocytes and depletes them via complement-dependent cytotoxicity and Fc-mediated antibody-dependent cytotoxicity/phagocytosis, reducing pathogenic B-cell antigen presentation and cytokine production. Targets: CD20+ mature B cells (sparing stem cells and plasma cells), pathways include complement activation and Fcγ receptor effector functions.